SCHEMBL3712042

SCHEMBL3712042

O=c1ccc2ccc(Nc3nc(N4CCC(CNCC(F)F)CC4)c4occc4n3)cc2[nH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 12/20 0.40
▸ TRPV1 Q8NER1 2/20 0.37
▸ JAK2 O60674 4/20 0.37
▸ ABL1 P00519 4/20 0.37
▸ LCK P06239 4/20 0.37
▸ FYN P06241 4/20 0.37
▸ RET P07949 4/20 0.37
▸ MAPK8 P45983 4/20 0.37
▸ TNK2 Q07912 4/20 0.37
▸ MAP4K2 Q12851 4/20 0.37
▸ LTK P29376 3/20 0.37
▸ NTRK2 Q16620 3/20 0.37
▸ DAPK3 O43293 2/20 0.37
▸ PAK4 O96013 2/20 0.37
▸ GRK5 P34947 2/20 0.37
▸ CSNK1A1 P48729 2/20 0.37
▸ TYRO3 Q06418 2/20 0.37
▸ ALK Q9UM73 2/20 0.37
▸ ROCK1 Q13464 2/20 0.37
▸ PIM1 P11309 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3698391 0.90 SYK (0.38) SYKJAK2ABL1LCKFYN
SCHEMBL3699582 0.90 SYK (0.40) SYKJAK2ABL1LCKFYN
SCHEMBL1709935 0.87 SYK (0.51) SYKTRPV1JAK2ABL1LCK
SCHEMBL3707439 0.87 TRPV1 (0.40) SYKTRPV1JAK2ABL1LCK
SCHEMBL3712696 0.87 TRPV1 (0.40) SYKTRPV1JAK2ABL1LCK
SCHEMBL1709768 0.83 SYK (0.44) SYKJAK2ABL1LCKFYN
SCHEMBL3711654 0.83 SYK (0.55) SYKJAK2ABL1LCKFYN
SCHEMBL1290676 0.82 SYK (0.49) SYKJAK2ABL1LCKFYN
SCHEMBL3715206 0.82 SYK (0.44) SYKTRPV1JAK2ABL1LCK
SCHEMBL3705364 0.82 SYK (0.45) SYKJAK2ABL1LCKFYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 — — US claimed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 — — US claimed
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 — — US disclosed
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 — — US disclosed
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 — — US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 — — US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 — — US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS CDK2, DPYD, CDK3 SYK 1176/4885TRPV1 1067/4885JAK2 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback